Meet the team who designed the Cochlear™ Baha® SoundArc, the new non-surgical bone conduction wearing option for pediatric patients. Learn how the engineers and designers drove innovation and filled the gap of a product that has never existed.
Meet the team who designed the Cochlear™ Baha® SoundArc
Jamie Schwartz
Related Posts
5 online bone conduction solutions resources
On-demand Osia® System webinar
This one-hour webinar provides an overview of the new Cochlear™ Osia® System, including topics such as candidacy, design features and surgical/audiological overviews. Also, hear from guest speaker Dr. Michael Oldenburg who shares his experience implanting this innovative system.
Fitting a Baha® SoundArc™ System videos
The SoundArc, part of the Baha® System, is a modern and discreet non-surgical option for children and adults struggling with conductive hearing loss, mixed hearing loss or single-sided deafness (SSD). It can be fit quickly and easily and can be used with any of the Baha 5 series of processors. Want more help fitting the SoundArc? These videos give clinicians the tools to correctly fit a SoundArc to maximize patients’ hearing performance:
Osia System Q&A
Dr. Abraham Jacob, Medical Director of Ear & Hearing at Center for Neurosciences in Tucson, Arizona, discusses the world’s first and only Active Osseointegrated Steady-State Implant (OSI). One of the initial surgeons to implant the Osia System, he uses 13 years of surgical cochlear implant/bone conduction experience to review his initial experience with the system.
Non-surgical Baha considerations
Lisa Christensen, AuD, is the Audiology Program Manager at Cook Children’s Medical Center in Fort Worth, Texas and former President of the American Academy of Audiology (AAA). Read her discussion on use of bone conduction solutions and non-surgical Baha options as part of her clinical practice.
Osia System resource guide
The Osia System is a first-of-its-kind hearing implant system for people with single-sided deafness (SSD), conductive or mixed hearing loss. Learn seven key facts to expand your knowledge about the new hearing loss solution and its technology.
For more information, subscribe to Cochlear ProNews or check out these AudiologyOnline resources.
In the United States, the Osia 2 System is indicated in children 12 and older.
In the United States and Canada, the placement of a bone conduction implant is contraindicated in Children under the age of 5.
Cochlear receives FDA clearance to lower the age for the Osia® System to 5 years old
- In the United States, the Osia System is now cleared for children ages 5 and older
- The Osia System, which launched commercially in 2020, is indicated for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD)
- The Osia System has been shown to provide clinically significant improvements high frequency hearing for children.2,3,4
Lone Tree, Colo. (April 19, 2024) – Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™ Osia System from 12 years-old to 5 years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).
The Osia System is a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the inner ear (cochlea). It is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery.1
Now children as young as 5 will be able to have full access to the Osia System’s unique technology that is optimized to deliver high power and clarity, especially in high-frequency sounds, which are important for hearing what others are saying.
“I love my Osia. It’s given me the confidence to succeed in school. I can hear everything my teacher and my friends say,” Adrian R., 8-year-old Osia System recipient said.
Adrian was diagnosed with hearing loss at age 4 and started with the Baha® Sound Processor with a Baha Softband before transitioning to the Osia System at age 6.
“It has been amazing to see the transformation in Adrian. She has been doing so well in school and is able to keep up with her friends both in school and out. She is even learning the piano now and I never thought I would be able to say that. It has truly been life changing,” Dea R., parent to 8-year-old Adrian said.
The Osia System has been shown to provide clinically significant improvements in high frequency hearing for children.2,3,4
“I choose the Osia System for my pediatric patients because it really made the difference in terms of the sound clarity. It is absolutely incredible,” Dr. Daniela Carvalho, Pediatric Otolaryngologist at Rady Children’s Hospital said.
“All of my patients with the Osia System have come back to my office saying it’s the first time they’ve heard the birds chirping or other high-frequency sounds.”
Cochlear’s product portfolio is inspired by meaningful innovation and a core belief that technology is only as useful as the benefit it provides.
“The Osia System is transformative technology, and we’re pleased that it’s now accessible for children as young as 5. This aligns with our commitment to empower people across all stages of life to stay connected and thrive,” Lisa Aubert, President, Cochlear North America said.
About Cochlear Limited (ASX: COH)
People have always been Cochlear’s inspiration, ever since Professor Graeme Clark set out to create the first multi-channel cochlear implant after seeing his father struggle with hearing loss. Since 1981, Cochlear has provided more than 750,000 devices in more than 180 countries, helping people of all ages around the world to hear. As the global leader in implantable hearing solutions, Cochlear connects people with life’s opportunities, and welcomes them to the world’s largest hearing implant community.
Cochlear has a global workforce of around 4,800 people, with a passion for progress, who strive to meet the needs of people living with hearing loss. The company continually innovates to anticipate future needs, investing more than AUD$2.7 billion to date in research and development to push the boundaries of technology and help more people hear.
For further information please contact:
Christy LaPlante – PR Manager Cochlear Americas
E: pr-cochlearamericas@cochlear.com
- Ellsperman SE, Nairn EM, Stucken EZ. Review of Bone Conduction Hearing Devices. Audiol Res. 2021;11(2):207-219.
- ClinicalTrials.Gov ID NCT 0500931
- You, P., A. Choi, J. Drob, S. M. Hunsaker, Y. C. Liu, and R. Silva. 2022. ‘Early Outcomes of a New Active Transcutaneous Bone Conduction Implant in Pediatric Patients’, Otol Neurotol, 43: 212-18.
- Florentine, M. M., J. Virbalas, and D. K. Chan. 2022. ‘Early surgical and audiologic outcomes of active, transcutaneous, osseointegrated bone-conduction hearing device (Osia 2® system) placement’, International Journal of Pediatric Otorhinolaryngology, 156.
In the United States and Canada, the Osia System is indicated for ages 5 and older.
© Cochlear Limited 2024. All rights reserved.